Hetero Biopharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Hetero Biopharma Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $600.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hetero Biopharma Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $600.0K Trade | TransData Nexus

Hetero Biopharma Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $600.0K Total Trade · DGFT Verified

Hetero Biopharma Limited is an Indian pharmaceutical exporter with a total trade value of $600.0K across 2 products in 1 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rituximab ($400.0K), Bevacizumab ($200.0K), .

Hetero Biopharma Limited — Export Portfolio & Destination Treemap

Hetero Biopharma Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Hetero Biopharma Limited? — Company Overview & Market Position

Hetero Biopharma Limited, established in September 2016, is a public company incorporated under the Corporate Identification Number (CIN) U24290TG2016PLC111946. The company is headquartered in Hyderabad, Telangana, India, with its registered office located at G Block, East Wing, Challa Estates, Erra Gadda, Hyderabad. As of March 2025, Hetero Biopharma reported an authorized capital of ₹166 crore and a paid-up capital of ₹45.05 crore. The company operates in the pharmaceutical manufacturing sector, focusing on the production of biosimilars and other pharmaceutical formulations. Hetero Biopharma is a subsidiary of the Hetero Group, a prominent Indian pharmaceutical conglomerate. The company employs between 501 and 1,000 individuals, reflecting its significant presence in the industry.

What Does Hetero Biopharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Rituximab$400.0K 2Bevacizumab$200.0K

Product Portfolio — Top 2 by Export Value

Hetero Biopharma Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rituximab	Advanced Oncology	$400.0K	8	2.1%	5
2	Bevacizumab	Advanced Oncology	$200.0K	4	0.4%	9

Hetero Biopharma Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $600.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Hetero Biopharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Hetero Biopharma's manufacturing facilities are strategically located in Hyderabad, Telangana, India. The company has developed state-of-the-art manufacturing units equipped with the latest technology and equipment, ensuring the production of high-quality medicines. These facilities adhere to current Good Manufacturing Practice (cGMP) standards, reflecting the company's commitment to quality and regulatory compliance. The manufacturing units are designed to produce a range of pharmaceutical formulations, including biosimilars, tablets, capsules, syrups, and injections, catering to both domestic and international markets.

3Key Leadership

As of the latest available information, the key leadership team at Hetero Biopharma includes:

Parthasaradhi Reddy Bandi: Director since September 14, 2016.

Bandi Vamsikrishna: Director appointed on March 25, 2021.

Janardhan Katersala: Company Secretary, CFO, and Additional Director appointed on December 29, 2023.

Divyanshu Patidar: Company Secretary, CFO, and Additional Director appointed on September 30, 2023.

Govindaraju Bhavani: Director appointed on August 26, 2022.

Bhaskarreddy Pabbatireddy: Company Secretary, CFO, and Additional Director appointed on September 26, 2025.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Hetero Biopharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Hetero Biopharma has made significant strides in entering regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has filed for approvals of its biosimilar products in these regions, aiming to provide affordable alternatives to expensive biologic medicines. For instance, in 2014, Hetero Biopharma launched its first biosimilar product, Derise (Darbepoetin alfa), a biosimilar to Aranesp®, and became the second company globally to launch a Darbepoetin biosimilar. The company's commitment to quality and regulatory compliance is evident in its adherence to international standards, facilitating market access in these regions.

2Emerging Markets

Hetero Biopharma has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on biosimilars has enabled it to offer cost-effective treatment options in these regions, addressing the healthcare needs of a large population. By obtaining World Health Organization (WHO) prequalification, Hetero Biopharma has enhanced its credibility and facilitated smoother market entry in these emerging markets. The company's flexible business model and strategic partnerships have been instrumental in overcoming entry barriers and establishing a strong foothold in these regions.

Geographic Strategy

Hetero Biopharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Hetero Biopharma has engaged in the regulatory process for the U.S. market by filing for approvals of its biosimilar products. The company's commitment to quality and regulatory compliance is evident in its adherence to international standards, facilitating market access in the United States. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's proactive approach indicates a focus on meeting FDA requirements for market entry.

2WHO & EU GMP

Hetero Biopharma's commitment to quality is underscored by its adherence to Good Manufacturing Practice (GMP) standards recognized by the World Health Organization (WHO) and the European Union (EU). The company's manufacturing facilities are built and operated according to cGMP standards, ensuring the production of high-quality medicines. While specific certifications such as WHO prequalification and EU GMP certificates are not publicly detailed, the company's focus on quality and regulatory compliance suggests alignment with these international standards.

3CDSCO & Indian Regulatory

Hetero Biopharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Hetero Biopharma operates in a competitive landscape, particularly in the biosimilars segment, where it faces competition from both domestic and international players. The company's focus on affordability and accessibility positions it favorably in emerging markets, where there is a significant demand for cost-effective treatment options. While specific market share data is not publicly available, Hetero Biopharma's strategic partnerships and adherence to international quality standards enhance its competitive edge. The company's proactive approach to regulatory compliance and market entry further strengthens its position in the global pharmaceutical industry.

2Key Differentiators

Hetero Biopharma's key differentiators include its commitment to making complex biosimilars affordable, available, and accessible globally. The company's focus on biosimilars addresses the need for cost-effective alternatives to expensive biologic medicines, enhancing patient access to essential treatments. Additionally, Hetero Biopharma's flexible business model and strategic partnerships enable it to navigate diverse regulatory environments and market dynamics effectively. The company's adherence to international quality standards and its proactive approach to regulatory compliance further distinguish it in the pharmaceutical industry.

Strategic Position

Buyer Due Diligence Brief — Evaluating Hetero Biopharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Hetero Biopharma has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations. The company's export volume and consistency reflect its reliability as a supplier. While specific data on export volumes and consistency are not publicly disclosed, the company's strategic partnerships and adherence to international quality standards suggest a strong and reliable supply chain. Stakeholders are encouraged to conduct thorough due diligence to assess the company's current performance and reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and quality standards:

FDA Approval:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Hetero Biopharma Limited

How many pharmaceutical products does Hetero Biopharma Limited export from India?

Hetero Biopharma Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Rituximab ($400.0K), Bevacizumab ($200.0K). Total export value is $600.0K.

What is Hetero Biopharma Limited's total pharmaceutical export value?

Hetero Biopharma Limited's total pharmaceutical export value is $600.0K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Hetero Biopharma Limited cover?

Hetero Biopharma Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Hetero Biopharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.